Journal of Medicinal Chemistry · 2003 · 45 citations · 7 references
PharmacyMolecular PharmaceuticsOncologyCancer PharmacologyDrug DeliveryMolecular OncologyAntibody ConjugatesAntibody ConjugationAntibody-drug ConjugatesBioconjugation ChemistryCancer BiotechnologyConjugation ReactionsAntibody - Enzyme ConjugatesAntibody-drug Conjugate TherapyAntibody-enzyme ConjugatesAvidin-biotin Affinity SystemsConjugation Of Antibody FragmentsDrug-protein ConjugatesProtein-nanoparticle ConjugationTargeting Ligand Conjugation
The synthesis of a new biotin derivative, the (CO) reduced N-aminohexyl biotinamido derivative, designed to be serum biotinidase resistant, and its conjugation to the chelator DOTA through an amide bond at one of the four carboxymethyl chains are described. The (90)Y-labeled conjugate was able to bind avidin at different Av/conjugate molar ratios with good results. The preclinical results indicate that this new biotin-DOTA conjugate is a good candidate for pretargeted diagnosis and therapy of tumors.
7
Michael R. Lewis, Andrew Raubitschek, John E. Shively · Bioconjugate Chemistry · 1994 · 163 citations
Giovanni Paganelli, Mirco Bartolomei, Mahila Ferrari et al. · Cancer Biotherapy and Radiopharmaceuticals · 2001 · 131 citations